Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy

Epidermal growth factor receptor monoclonal antibody was approved for treatment of metastatic colorectal cancer patients carrying KRAS wild type DNA. However, recent studies showed that patients with KRAS G13D mutation may benefit from EGFR antibody therapy. In this study we tried to explore whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Shaorong, Xiao, Xia, Lu, Jianwei, Qian, Xiaoping, Liu, Baorui, Feng, Jifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706612/
https://www.ncbi.nlm.nih.gov/pubmed/23874486
http://dx.doi.org/10.1371/journal.pone.0068022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706612/
https://www.ncbi.nlm.nih.gov/pubmed/23874486
http://dx.doi.org/10.1371/journal.pone.0068022

Ejemplares similares